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The analysis of randomised controlled trials by sub-
groups of individuals (e.g. according to age or gender)
remains controversial and often misinterpreted. It is
recognised that such analyses should be limited to a few
pre-specified key baseline factors. In addition an appro-
priate analysis typically calculates effect estimates and
confidence intervals within such subgroups together
with an overall interaction test rather than calculating
separate p-values within each category of the subgroup.
However, patients vary considerably often presenting
with multiple risk factors for the outcome of interest.
Hence an alternative approach to analysing subgroups is
proposed whereby patients are analysed according to their
underlying risk rather than individual characteristics and a
single interaction test performed between underlying risk
and treatment. Patients can be categorised into several
ordered risk groups and the absolute and relative risk
reduction in each group presented. This helps the decision
making process for an individual patient when considering
appropriate treatment strategies. For instance, even if a
beneficial relative risk is steady across groups, the absolute
benefits in the low-risk group may be too small to justify
the new treatment’s use.
These issues will be illustrated using data from trials in
acute coronary syndrome. The FIR collaboration com-
bined data from three trials (FRISC-II, RITA-3 and
ICTUS) interventional and conservative strategies. The
ACUITY trial assessed the impact of three anti-thrombotic
therapies for reducing clinical outcomes and major
bleeding.
We recommend that risk stratified subgroup analyses
be routinely reported in trials that claim a treatment
benefit.
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